Nyrada (ASX:NYR) Market Cap: A$110.47 Mil (As of Jul. 01, 2026)


ASX:NYR Nyrada Inc ASX:NYR
25 GF Score
Price A$0.45
! 1 Warning Sign
View Full Analysis

What is Nyrada Market Cap?

Nyrada ASX:NYR +7.14% 25 Market Cap is A$110.47 Mil as of Jul. 01, 2026. GuruFocus rates ASX:NYR with a GF Score™ of 25/100. The stock has 1 warning sign investors should review. Among 1,428 Biotechnology companies, Nyrada ranks worse than 58.19% on this metric.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Nyrada's share price for the quarter that ended in Dec. 2025 was A$1.12. Nyrada's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 243.26 Mil. Therefore, Nyrada's market cap for the quarter that ended in Dec. 2025 was A$272.45 Mil.

Nyrada's quarterly market cap increased from Dec. 2024 (A$19.77 Mil) to Jun. 2025 (A$50.62 Mil) and increased from Jun. 2025 (A$50.62 Mil) to Dec. 2025 (A$272.45 Mil).

Nyrada's annual market cap increased from Jun. 2023 (A$4.37 Mil) to Jun. 2024 (A$10.75 Mil) and increased from Jun. 2024 (A$10.75 Mil) to Jun. 2025 (A$50.62 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Nyrada's Enterprise Value for Today is A$103.35 Mil.


Nyrada  (ASX:NYR) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Nyrada Market Cap Related Terms


Nyrada Market Cap Historical Data

* Premium members only.

The historical data trend for Nyrada's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nyrada Market Cap Chart

Nyrada Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Market Cap
Get a 7-Day Free Trial 49.92 21.06 4.37 10.75 50.62

Nyrada Semi-Annual Data
Jun19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.43 10.75 19.77 50.62 272.45

ASX:NYR vs VRTX, REGN, ALNY: Market Cap Comparison

For the Biotechnology subindustry, Nyrada's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nyrada Market Cap vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nyrada's Market Cap distribution charts can be found below:

* The bar in red indicates where Nyrada's Market Cap falls into.


ASX:NYR
25GF Score
Nyrada Inc ASX:NYR
Market Cap is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nyrada Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Nyrada's Market Cap for the fiscal year that ended in Jun. 2025 is calculated as

Market Cap (A: Jun. 2025 )=Share Price (A: Jun. 2025 )*Shares Outstanding (EOP) (A: Jun. 2025 )
=A$0.24*210.917
=A$50.62

Nyrada's Market Cap for the quarter that ended in Dec. 2025 is calculated as

Market Cap (Q: Dec. 2025 )=Share Price (Q: Dec. 2025 )*Shares Outstanding (EOP) (Q: Dec. 2025 )
=A$1.12*243.259
=A$272.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of A$110.47 Mil mean?
Nyrada (ASX:NYR) has a Market Cap of A$110.47 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Nyrada and its competitors. According to the industry distribution chart, Nyrada ranks #831 out of 1428 companies in the Biotechnology industry, placing it in the top 58.2%.
Is Nyrada's Market Cap too high?
Nyrada's current Market Cap is A$110.47 Mil. Based on the distribution chart, Nyrada ranks #831 out of 1428 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Nyrada has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Nyrada's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nyrada ranks #831 out of 1428 companies for Market Cap. This places Nyrada in the lower half of its industry. The industry median Market Cap is 119.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.44, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Nyrada and its competitors. For the Biotechnology industry, the median Market Cap is 119.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nyrada's current Market Cap is A$110.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nyrada stock overvalued right now?
Nyrada (ASX:NYR) has a current Market Cap of A$110.47 Mil. The current Market Cap is A$110.47 Mil. Nyrada's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Nyrada (ASX:NYR), the current Market Cap is A$110.47 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nyrada Business Description

Address 180 George Street, Sydney Place, Level 22/23, Salesforce Tower, Sydney, NSW, AUS, 2000
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. It operates in one segment: research and development of drugs focusing on small molecules with potential therapeutic benefit in areas of medical needs. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.
25GF Score

Get the complete analysis for ASX:NYR

Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.45
Price